Tingsheng Technology is a technology company.
Tingsheng Technology has raised $24.0M across 2 funding rounds.
Tingsheng Technology has raised $24.0M in total across 2 funding rounds.
Tingsheng Technology has raised $24.0M in total across 2 funding rounds.
Tingsheng Technology's investors include Qiming Venture Partners.
Tingsheng Technology (TINGSN) is a Chinese medtech company specializing in intracardiac echocardiography (ICE) products for cardiac electrophysiological interventions, particularly treating arrhythmias through advanced ultrasound imaging catheters.[1][2][3][4][8] Founded in 2017 and based in Jiangsu Province, it develops Class III medical devices like 2D and 4D ICE systems, serving interventional cardiologists and electrophysiologists by enabling real-time imaging during minimally invasive procedures.[1][5][6][8] The company solves critical needs in cardiac ablation by providing domestic alternatives to imported systems, with its 2D ICE being China's first to gain fast-track approval and achieve commercial success; it recently raised nearly 100 million yuan in Series B+ funding (led by Yifeng Capital) to advance 4D ICE R&D, clinical trials, and mass production.[1][5]
Established in 2017 in Jiangsu Sheng, China, Tingsheng Technology emerged to address gaps in domestic cardiac imaging tech amid growing electrophysiology demands.[1][5] The team, boasting strong medical-engineering integration, drew on profound technical expertise and commercialization experience to pioneer self-developed transducers—the first in China—marking "zero breakthroughs" from 2D ICE (fast-tracked certification and sales) to 4D ICE and ASIC chip tape-out.[1] Over seven years, pivotal moments include launching products like TINGSN FINDERS 1 (single-use ICE catheter) and building high-end manufacturing for micron-level precision, propelling it toward global competitiveness with a vision of creating an influential Chinese medical device brand.[1][8]
Tingsheng rides China's booming electrophysiology market, driven by rising cardiac arrhythmia cases and policy pushes for medtech self-reliance via green channels and domestic substitution.[1] Timing aligns with global ICE demand (dominated by imports) and local growth in minimally invasive interventions, where high-res imaging reduces procedure risks and costs.[1][3][4] Market forces like funding influx (Qiming, Yifeng) and technical hurdles in transducers favor innovators like Tingsheng, influencing the ecosystem by localizing supply chains, boosting R&D in Class III devices, and elevating Chinese brands in international cardiac tech.[1][5][6]
Tingsheng is poised for mass production of 4D ICE post-funding, targeting broader electrophysiology adoption and exports as clinical data strengthens.[1] Trends like AI-enhanced imaging, precision ablation, and China's medtech boom will amplify its trajectory, potentially evolving it into a global player via partnerships and further "zero breakthroughs."[1] With funding securing R&D and scaling, expect accelerated revenue from commercial wins, circling back to its mission: escorting health through cutting-edge, trustworthy tech.[1][8]
Tingsheng Technology has raised $24.0M across 2 funding rounds. Most recently, it raised $8.0M Series B in July 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2024 | $8.0M Series B | Qiming Venture Partners | |
| Mar 1, 2022 | $16.0M Series A | Qiming Venture Partners |